Published Paper Details:

Hypertension is chronic condition which mostly needs combination treatment for effective clinical management of the disease. Nebivolol is beta blocker agent used to reduce heart rate and hypertension while indapamide is a thiazide diuretics used to remove excess water thus to reduce hypertension. Nebivolol and Indapamide are being used in combination to treat heart failure and hypertension. In present research work, a bilayer tablet formulation containing sustained release indapamide part and immediate release Nebivolol part was prepared and evaluated. Results of the compatibility study revealed that both drugs are compatible with each other as well as with the excipients used in the formulation. Six trial batches of Sustained release Indapamide tablet were prepared using varying amount of HPMC K5, K15 and K100. Batch S6 prepared with HPMC K100 showed optimum drug release and other in vitro parameters. Immediate release layer was also prepared using wet granulation method. Amount of pregelitinised starch, SLS and Croscarmelose sodium was optimized. Among different trials, trial S6 for indapamide SR part and trial I10 for nebivolol IR part showed satisfactory in vitro dissolution profile so these two were selected for the preparation of bilayer tablets. Dissolution profiles of drugs in bilayer tablet were very similar to that of individual part. In vitro evaluation parameters for both individual part and bilayer tablet were found to be in specified and acceptable range. The result of stability study showed no significant change in physical and chemical parameters of the tablet; hence the formulation was found to be stable.